Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 24.2351
- Book/Share 28.0812
- PB 4.7816
- Debt/Equity 0.2713
- CurrentRatio 1.7805
- ROIC 0.1913
- MktCap 232407827200.0
- FreeCF/Share 3.8101
- PFCF 34.9118
- PE 17.2859
- Debt/Assets 0.1626
- DivYield 0.0171
- ROE 0.3076
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Read More
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries ABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary …
Read More
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Read More
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Published: March 04, 2025 by: Business Wire
Sentiment: Neutral
WAYNE, Penn.--(BUSINESS WIRE)-- #CLI--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent.
Read More
My Best Dividend Aristocrats For March 2025
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
The latest trading day saw Abbott (ABT) settling at $133.17, representing a +0.79% change from its previous close.
Read More
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Read More
AHCO or ABT: Which Is the Better Value Stock Right Now?
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either AdaptHealth Corp. (AHCO) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Mr. Robert B. Ford
- Employees 114000